PENGUIN: PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 22
- 试验地点
- 1
- 主要终点
- Renal oxygen consumption
研究概览
简要总结
Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic cause of end-stage kidney disease (ESKD). The disorder is characterized by development and continued growth of multiple cysts requiring renal replacement therapy in 50% of patients by age 60 years. However, ADPKD is also a complex metabolic disorder defined by insulin resistance (IR) and mitochondrial dysfunction which may be causally related to cyst expansion, kidney function decline and contribute to reduced life expectancy. Renal hypoxia, stemming from a potential metabolic mismatch between increased renal energy expenditure and impaired substrate utilization, is proposed as a novel unifying early pathway in the development and expansion of renal cysts in ADPKD. By examining the interplay between renal O2 consumption and energy utilization in young adults with and without ADPKD, the investigators hope to identify novel therapeutic targets to impede development of cyst expansion in future trials.
The investigators propose to address the specific aims in a cross-sectional study with 20 adults with ADPKD (50% female, ages 18-40 years). Comparative data will be provided from healthy adults from an ongoing study with similar study design and methods (CROCODILE Study: Control of Renal Oxygen Consumption, Mitochondrial Dysfunction, and Insulin Resistance). For this protocol, participants will complete a one day study visit at Children's Hospital Colorado. Patients will undergo a dual energy x-ray absorptiometry (DXA) to assess body composition, and a 11C-acetate positron emission tomography (PET/CT) scan to quantify renal O2 consumption. After the PET/CT, participants will undergo a hyperinsulinemic-euglycemic clamp while fasting to quantify insulin sensitivity. Glomerular Filtration Rate (GFR) and Effective Renal Plasma Flow (ERPF) will be measured by iohexol and PAH clearances during the hyperinsulinemic-euglycemic clamp.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 40 Years(Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with Autosomal dominant polycystic kidney disease
- •Age 18-40 years
- •BMI >= 18.5 and <30 kg/m2
- •Weight <350 lbs
排除标准
- •Diabetes mellitus, based on previous diagnosis
- •Albuminuria (≥30mg/g) or estimated glomerular filtration rate (eGFR) <75ml/min/1.73m2
- •Pregnancy or nursing
- •Allergy to shellfish or iodine
- •Vaptan therapy (e.g. tolvaptan)
- •Uncontrolled hypertension (average ≥140/90 mmHg)
研究组 & 干预措施
Adults with autosomal dominant polycystic kidney disease
All participants will undergo DXA scan, PET/CT using 11-C acetate to measure renal oxygen consumption, hyperinsulinemic-euglycemic clamp to quantify insulin sensitivity, and renal clearance testing using iohexol and para-aminohippurate (PAH) to quantify glomerular filtration rate (GFR) and effective renal plasma flow (ERPF).
干预措施: Aminohippurate Sodium Inj 20% (Drug)
Adults with autosomal dominant polycystic kidney disease
All participants will undergo DXA scan, PET/CT using 11-C acetate to measure renal oxygen consumption, hyperinsulinemic-euglycemic clamp to quantify insulin sensitivity, and renal clearance testing using iohexol and para-aminohippurate (PAH) to quantify glomerular filtration rate (GFR) and effective renal plasma flow (ERPF).
干预措施: Iohexol Inj 300 milligrams per milliliter (MG/ML) (Drug)
Adults with autosomal dominant polycystic kidney disease
All participants will undergo DXA scan, PET/CT using 11-C acetate to measure renal oxygen consumption, hyperinsulinemic-euglycemic clamp to quantify insulin sensitivity, and renal clearance testing using iohexol and para-aminohippurate (PAH) to quantify glomerular filtration rate (GFR) and effective renal plasma flow (ERPF).
干预措施: PET/CT Scan (Radiation)
结局指标
主要结局
Renal oxygen consumption
时间窗: 30 minutes
11-C Acetate PET/CT
Insulin Sensitivity
时间窗: 4.5 hours
Hyperinsulinemic-Euglycemic Clamp
次要结局
- Renin-Angiotensin-Aldosterone-System Activity(5 minutes)
- Kidney Injury Biomarkers(5 minutes)
- Glomerular Filtration Rate (GFR)(3 hours)
- Effective Renal Plasma Flow (ERPF)(2.5 hours)
- Mitochondrial Function(5 minutes)
